Treatment with powdered intranasal epinephrine
AssigneeNasus Pharma Ltd.
InventorsGalia Temtsin-Krayz, Pavel Kazhdan
Life of this patent
Estimating the term…
Abstract
Disclosed is a pharmaceutical composition in dry powder form for intranasal administration, comprising an anti-anaphylactic adrenergic receptor agonist in the form of dry powder for intranasal administration, the composition comprising solid particles of the active agent in combination with at least one functional additive, and solid particles of an inert carrier.
Claims13
A pharmaceutical composition comprising as an active agent an anti-anaphylactic adrenergic receptor agonist in the form of dry powder for intranasal administration, said composition comprising a first type of solid essentially spherical particles of a homogenous combination of said active agent in combination with at least one functional additive, and a second type of solid particles comprising a pharmaceutically acceptable carrier, wherein at least about 90% of said first type particles are of a mean particle size of about 10-30 microns and less than about 10% of said first type particles are of a mean particle size equal to or below about 10 microns and said second type particles are of a mean particle size of about 50-200 microns.
An epinephrine pharmaceutical composition in the form of dry powder for intranasal administration, comprising as active agent epinephrine bitartrate, said composition comprising a first type of solid spherical particles comprising epinephrine bitartrate in combination with sodium di-hydrogen phosphate, and a second type of irregular solid particles comprising lactose monohydrate as carrier, wherein said first type spherical particles have a narrow size distribution of 5-30 μm, and are dispersed between said irregular particles of lactose ranging between 40 μm to 240 μm, providing a metered therapeutically effective nominal dose of said epinephrine bitartrate.
An epinephrine pharmaceutical composition in the form of dry powder for intranasal administration, comprising as active agent epinephrine bitartrate, said composition comprising a first type of solid spherical particles comprising epinephrine bitartrate in combination with sodium di-hydrogen phosphate, and a second type of irregular solid particles comprising lactose monohydrate as carrier, wherein the size distribution of the first type of solid spherical particles as determined by Malvern Laser Diffraction instrument is D=21.4 μm, D (50)=82.0 μm and D (90)=133 μm, and wherein the amount of the obtained particles having the size less than 10 μm is about 3.7% v/v and of particles having the size of less than 5 μm is about 2.8% v/v, providing a metered therapeutically effective nominal dose of said epinephrine or pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.